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•Grades I and II aGHVD
favorably affect survival




Allogeneic hematopoietic cell transplant is a potential curative therapy for acute lymphoblastic
leukemia (ALL). Delineating the graft-versus-leukemia (GVL) effect as a function of graft-
versus-host disease (GVHD) offers the potential to improve survival. We examined 5215
transplant recipients with ALL reported to the Center for International Blood and Marrow
Transplant Research registry. Overall survival (OS) was compared according to the presence
and severity of GVHD and evaluated in 3 cohorts: 2593 adults in ﬁrst or second complete
remission (CR1/CR2), 1619 pediatric patients in CR1/CR2, and 1003 patients with advanced
(CR$3 or active disease) ALL. For patients in CR1/CR2, development of acute GVHD (aGVHD)
or chronic GVHD (cGVHD) was associated with lower risk of relapse than no GVHD (hazard
ratio [HR], 0.49-0.69). Patients with advanced ALL developing grades III and IV aGVHD or
cGVHD were also at lower risk of relapse (HRs varied from 0.52 to 0.67). Importantly, adult
and children in CR1/CR2 with grades I and II aGVHD without cGVHD experienced the best OS
compared with no GVHD (reduction of mortality with HR, 0.83-0.76). Increased nonrelapse
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mortality accompanied grades III and IV aGVHD (HRs varied from 2.69 to 3.91) in all 3 cohorts
and abrogated any protection from relapse, resulting in inferior OS. Patients with advanced
ALL had better OS (reduction inmortality; HR, 0.69-0.73) when they developed cGVHDwith or
without grades I and II aGVHD. In conclusion, GVHD was associated with an increased GVL
effect in ALL. GVL exerted a net beneﬁcial effect on OS only if associated with low-grade
aGVHD in CR1/CR2 or with cGVHD in advanced ALL.
Introduction
The graft-versus-leukemia (GVL) effect associated with allogeneic
hematopoietic cell transplant (alloHCT) provides potent antileuke-
mic therapy for patients with acute lymphoblastic leukemia (ALL) as
reflected by a significantly reduced relapse rate compared with
standard chemotherapy or autologous HCT.1 Although the GVL
effect may occur in the absence of clinical graft-versus-host disease
(GVHD), data suggest that acute GVHD (aGVHD) and chronic
GVHD (cGVHD) are associated with an augmented GVL effect.2-13
Nevertheless, GVHD affecting .50% of patients remains a major
cause of mortality after alloHCT. Hence, the increased nonrelapse
mortality (NRM) associated with GVHD may abrogate the favorable
GVL effect on disease relapse. The strength of the GVL effect has
been shown to differ between hematological malignancies.14 As
shown in a large registry study, acute myeloid leukemia (AML) was
relatively insensitive to aGVHD and limited cGVHD; nevertheless,
reductions in relapse risk have been reported in patients experi-
encing extensive cGVHD. Conversely, ALL was sensitive to both
aGVHD and cGVHD, with reduced relapse risks comparable to
chronic myeloid leukemia. In fact, the higher sensitivity of ALL to
GVHD compared with AML was first described in 1979 in a cohort
of allogeneic and syngeneic marrow transplants.15 Accordingly, the
net impact of aGVHD and cGVHD on survival may differ consid-
erably between patients with AML and ALL.10,14,16 Although the
net impact of GVHD on transplant outcomes has been explored
in AML, robust studies in the modern era are lacking in ALL.12,13
Thus, the aim of the present Center for International Blood and
Marrow Transplant Research (CIBMTR) registry-led study was to
explore the impact of aGVHD and cGVHD of varying severity on




The CIBMTR is a combined research program of the Medical
College of Wisconsin and the National Marrow Donor Program.
CIBMTR comprises a voluntary network of .450 transplantation
centers worldwide that contribute detailed data on consecutive
alloHCT and autologous HCT to a centralized statistical center.
Observational studies conducted by CIBMTR are performed in
compliance with all applicable federal regulations pertaining to the
protection of human research participants.17
Study design
This retrospective study was designed to explore the GVL effect in
ALL and the impact of aGVHD and cGVHD on transplant-related
outcomes, including NRM, relapse, disease-free survival (DFS), and
overall survival (OS). The study population consisted of patients
with ALL who underwent alloHCT and who met all the following
criteria: (1) age .1 year at HCT; (2) first alloHCT; (3) adult (aged
.18 years) patients in first or second complete remission (CR1/
CR2) with any conditioning regimen intensity or pediatric (#18
years) patients in CR1/CR2 with myeloablative (MAC) regimens
only or patients of all ages in CR $3 or with active ALL with MAC
regimens only; (4) recipients of grafts from matched sibling (MSD),
unrelated (MUD), single or double umbilical cord blood (UCB)
donors; (5) transplanted between the years 2000 and 2014; and
(6) reported to the CIBMTR. Patients were excluded if they met
one or more of the following criteria: (1) haploidentical grafts
(as too few were available for inclusion); (2) donor-recipient HLA
disparity unknown; (3) ex vivo T-cell–depleted grafts; (4) failure to
engraft; (5) recipients of planned or preemptive donor lymphocyte
infusion; (6) no 100-day comprehensive research form available;
and (7) no signed informed consent available for data inclusion.
The following GVHD patient groups were compared: no GVHD vs
grades I and II aGVHD or grades III and IV aGVHD; and no cGVHD
vs cGVHD with or without preceding grades I and II or grades III and
IV aGVHD.
These three distinct patient cohorts were separately analyzed: (1) adult
patients in CR1/CR2withMACor reduced intensity conditioning (RIC)
regimens; (2) pediatric patients in CR1/CR2 with MAC regimens; and
(3) patients of all ages with advanced disease with MAC regimens.
Definitions
Advanced disease was defined as ALL in CR $3 and any patient
with active disease (primary induction failure or resistant relapse).
Cytogenetic abnormalities considered as adverse included t(9;22),
t(4;11), t(8;14), t(14;18), hypodiploid, and complex karyotype. Con-
ditioning regimen intensity was defined according to CIBMTR
criteria,18 and aGVHD and cGVHD were diagnosed and graded
according to consensus criteria.19,20 NRM was defined as death
during continuous CR after alloHCT. Relapse was defined as
clinical or hematological leukemia recurrence. For analyses of DFS,
failures were clinical or hematological relapses or deaths from any
cause. For OS analyses, failure was death from any cause.
Statistical analysis
Cumulative incidence curves were used for relapse incidence
and NRM considering each other as competing risk. Probabilities of
DFS and OS were calculated by using Kaplan-Meier estimates.
Time-dependent analysis was performed for each of the 3 distinct
cohorts examining the main GVHD patient groups: no GVHD vs
grades I and II aGVHD; no GVHD vs grades III and IV aGVHD; no
GVHD vs cGVHD; no GVHD vs grades I and II aGVHD plus
cGVHD; and no GVHD vs grades III and IV aGVHD plus cGVHD.
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Assessment of GVHD and GVL effects were evaluated in multivar-
iate analysis (MVA) by using Cox models for treatment failure
(1-DFS) and overall mortality (1-OS), in which GVHD of the specified
grade or onset type was treated as a time-dependent covariate21,22
and in cumulative incidence competing hazards modeling for
relapse and NRM. Multivariate models considered the following
additional factors (Table 1): patient age, sex, Karnofsky perfor-
mance status (KPS) scores (,90% vs $90%), HCT–comorbidity
index (0 vs 1 vs 2 vs$3), leukocyte count at diagnosis according to
age group and cell lineage (T-cell,#1003 109/L vs.1003 109/L;
B-cell pediatric, #30 3 109/L vs 30 to 50 3 109/L vs .50 3 109/L;
and B-cell adults, #50 3 109/L vs .50 3 109/L), extramedullary
disease at diagnosis, cytogenetic risk group (normal/standard [SR]
vs Philadelphia-positive vs other poor risk), time to achieve CR1
(,4 weeks vs 4-8 weeks vs .8 weeks), time from diagnosis to
HCT for patients in CR1 (,6 months vs 6-12 months vs .12
months), conditioning regimen (total body irradiation [TBI]–based
MAC vs non-TBI–based MAC vs RIC), graft type (bone marrow vs
peripheral blood vs UCB), donor type and HLA match (MSD vs
MUD [8/8] vs 1 antigen or allele mismatch unrelated donor [URD]
[7/8] vs .1 antigen or allele mismatch URD [,7/8] vs UCB),
donor–recipient sex combination, donor–recipient cytomegalovirus
(CMV) serostatus, URD age (18-29 years vs 30-44 years
vs $45 years), GVHD prophylaxis (calcineurin inhibitor [CNI] plus
methotrexate vs CNI plus mycophenolate mofetil vs other), in vivo
T-cell depletion (using antithymocyte globulin or alemtuzumab), and
year of transplantation (2000-2003 vs 2004-2007 vs 2008-2011
vs 2012-2014).
A stepwise model selection approach was used, and each step
contained the main effect for GVHD. Factors that were significant at
a 5% level were kept in the final model. The proportionality assump-
tion was tested by adding a time-dependent covariate for each
factor. When tests indicated differential effects over time (non-
proportional hazards), models were constructed breaking the
posttransplant course into 2 time periods, using the maximized
partial likelihood method to find the most appropriate breakpoint.
After the aforementioned modeling of time-varying effects, the final
multivariate model was built.
Results
Patient, disease, and transplant characteristics
Overall, 5215 patients from 287 centers were eligible for analysis.
Cohort 1 included 2593 adult patients (median age, 36 years;
range, 18-75 years) in CR1/CR2 with MAC or RIC regimens;
cohort 2 included 1619 pediatric patients (median age, 9 years;
range, 1-18 years) in CR1/CR2 with MAC regimens; and cohort 3
included 1003 adult and pediatric patients (median age, 21 years;
range, 1-67 years) in CR $3 (n 5 403) and patients with active
disease (primary induction failure, n 5 145; relapse, n 5 455)
treated with MAC regimens.
Patient, disease, and treatment characteristics of the 3 cohorts are
summarized in Table 1. Most (88%) patients were aged,50 years,
61.5% were male, and 26% had Philadelphia-positive ALL. In
cohorts 1 and 2, 70% of adults and 40% of pediatric-aged patients
were in CR1. Data on minimal residual disease (MRD) were
available for only 16% of patients and thus were not considered
in any analyses. MAC regimens were used in 86% of adults in
CR1/CR2, and 28% received in vivo T-cell depletion.
Transplant outcomes
The median follow-up of survivors was 72 months (range, 3-191
months). At the time of analysis, 48% (2519 of 5215) of patients
were alive. The 1- and 5-year cumulative incidence rates of relapsewere
24% and 33%, respectively, and the corresponding NRM rates were
19% and 26%. The cumulative incidences of grades I to IV aGVHD by
day 100 in the 3 cohorts were 59%, 61%, and 65%, and the cumulative
incidences of cGVHD at 1 year were 46%, 29%, and 29%. The
cumulative incidences of relapse and NRM and survival curves of DFS
and OS in the 3 cohorts are shown in Figure 1.
Adult patients in CR1/CR2
Influence of aGVHD and cGVHD on transplant outcomes.
The median follow-up of survivors was 70 months (range, 2-184
months). At the time of analysis, 48% (1250 of 2593) of adult patients
in CR1/CR2 were alive, and 451 (17%), 640 (25%), 358 (14%),
and 146 (6%) patients developed grades I, II, III, and IV aGVHD,
respectively. The cumulative incidences of grades I and II and grades
III and IV aGVHD by day 100 were 41% and 18%. The cumulative
incidence of cGVHD at 1 year was 46%, and 22% never developed
GVHD. The 1- and 5-year cumulative incidence rates of relapse
were 21% and 32%, and the corresponding NRM rates were 20%
and 29%. The 1- and 5-year OS rates were 68% and 45%.
In MVA, using no GVHD as the reference category, all forms of
GVHD were protective against leukemia relapse (hazard ratio [HR],
0.49-0.70). Conversely, grades III and IV aGVHD and cGVHD were
each associated with increased risk of NRM (HR, 3.91 [95% CI,
3.12-4.91]; HR,1.93 [95% CI, 1.42-2.63], respectively). Compared
with patients without GVHD, these differential effects translated
into the following: (1) significantly improved DFS (HR, 0.74; 95%
CI, 0.63-0.86) and OS (HR, 0.83; 95% CI, 0.69-0.97) with grades I
and II aGVHD; (2) significantly worse DFS and OS with grades III
and IV aGVHD with or without cGVHD (HR, 1.36 [95% CI, 1.10-
1.68] and HR, 1.49 [95% CI, 1.20-1.85], with cGVHD; HR, 1.77
[95% CI, 1.50-2.08] and HR, 2.49 [95% CI, 2.09-2.96], without
cGVHD); and (3) similar DFS and OS with cGVHD, with or without
grades I and II aGVHD (Figure 2).
MVA of other factors affecting OS. In the adult cohort,
overall mortality increased with patient age $40 years and KPS
scores ,90%. Patients with Philadelphia-positive ALL had better
OS than patients with SR-cytogenetics, whereas patients with
poor and SR-cytogenetics had similar outcomes. TBI-based MAC
compared favorably with non-TBI–based MAC; however, the
number of patients receiving non-TBI–based MAC was disproportion-
ally smaller (12%). Survival was similar among patients who received
TBI-based MAC regimens and RIC/nonmyeloablative regimens.
Survival was similar using either MSD, MUD, or UCB but significantly
worse using mismatched URD. Other favorable factors included
CMV-seronegative patients with CMV-seropositive donors, GVHD
prophylaxis comprising a CNI plus methotrexate, and transplants in
the more recent era (Table 2). Subgroup analyses yielded similar
results within the CR1 and CR2 cohorts (data not shown).
Pediatric patients in CR1/CR2
Influence of aGVHD and cGVHD on transplant outcomes.
The median follow-up of survivors was 72 months (range, 2-191
months). At the time of analysis, 60% (976 of 1619) of pediatric
patients in CR1/CR2 were alive, and 357 (22%), 344 (21%), 210
(13%), and 99 (6%) patients developed grades I, II, III, and IV
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Table 1. Characteristics of study population
Variable Adults, CR1/CR2, MAC/RIC Pediatrics, CR1/CR2, MAC All ages PIF/relapse/CR ‡3, MAC
No. of patients 2593 1619 1003
No. of centers 232 165 205
Patient age, y
1-9 0 941 (58) 187 (19)
10-18 0 678 (42) 225 (22)
19-29 928 (36) 0 281 (28)
30-39 568 (22) 0 139 (14)
40-49 558 (22) 0 107 (11)
50-59 402 (16) 0 57 (6)
$60 137 (5) 0 7 (,1)
Median (range) 36 (18-75) 9 (1-18) 21 (1-67)
Sex
Male 1537 (59) 1018 (63) 651 (65)
Female 1056 (41) 601 (37) 352 (35)
KPS score
,90% 733 (28) 205 (13) 293 (29)
$90% 1774 (68) 1345 (83) 648 (65)
Missing 86 (3) 69 (4) 62 (6)
HCT–comorbidity index
0 518 (20) 449 (28) 157 (16)
1 165 (6) 46 (3) 30 (3)
2 129 (5) 14 (,1) 18 (2)
$3 283 (11) 34 (2) 45 (4)
NA 1498 (58) 1076 (66) 753 (75)
Philadelphia positive
No 1574 (61) 1315 (81) 813 (81)
Yes 957 (37) 249 (15) 150 (15)
Missing or untested 62 (2) 55 (3) 40 (4)
Immunophenotype
T cell 381 (15) 262 (16) 128 (13)
B cell 2119 (82) 1248 (77) 804 (80)
Missing 93 (4) 109 (7) 71 (7)
WBC at diagnosis by age group and lineage, 3 109/L
T, #100 214 (8) 105 (6) 70 (7)
T, .100 66 (3) 112 (7) 30 (3)
Adult B, #30 1200 (46) 0 216 (22)
Adult B, .30 531 (20) 0 124 (12)
Pediatric B, #30 0 646 (40) 157 (16)
Pediatric B, 30-50 0 86 (5) 31 (3)
Pediatric B, .50 0 276 (17) 54 (5)
Missing (WBC or lineage) 582 (22) 394 (24) 321 (32)
Extramedullary disease at diagnosis
No 2171 (84) 1301 (80) 819 (82)
Yes 328 (13) 270 (17) 146 (15)
Missing 94 (4) 48 (3) 38 (4)
Data are n (%) unless otherwise indicated.
ATG, antithymocyte globulin; CNS, central nervous system; NA, not applicable (before the year 2007); PIF, primary induction failure; TCD, T-cell depletion; TKI, tyrosine kinase inhibitor; WBC, white blood cell.
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Table 1. (continued)
Variable Adults, CR1/CR2, MAC/RIC Pediatrics, CR1/CR2, MAC All ages PIF/relapse/CR ‡3, MAC
Previous CNS disease
No 2330 (90) 1360 (84) 871 (87)
Yes 169 (7) 211 (13) 94 (9)
Missing 94 (4) 48 (3) 38 (4)
Disease status before HCT
Primary induction failure 0 0 145 (14)
CR1 1815 (70) 644 (40) 0
CR2 778 (30) 975 (60) 0
CR $3 0 0 403 (40)
Relapse 0 0 455 (45)
Cytogenetics scoring
Normal karyotype 768 (30) 400 (25) 301 (30)
Philadelphia chromosome 957 (37) 249 (15) 150 (15)
Other poor risk 230 (9) 281 (17) 95 (9)
SR 428 (17) 460 (28) 212 (21)
Not tested/missing 210 (8) 229 (14) 245 (24)
MRD at time of HCT
No 183 (7) 109 (7) 25 (2)
Yes 326 (13) 134 (8) 56 (6)
Missing 2084 (80) 1376 (85) 922 (92)
Time from diagnosis to HCT (CR1 cases)
,6 mo 1120 (43) 378 (23) 0
6-12 mo 602 (23) 217 (13) 0
.12 mo 93 (4) 49 (3) 0
Not applicable (CR21/PIF/relapse) 778 (30) 975 (60) 1003
Median (range) 7 (,1-21) 17 (,1-44)
Time to achieve CR1, median (range), wk 7 (,1-113) 5 (,1-167) 5 (,1-252)
Conditioning regimen
MAC with TBI 1917 (74) 1478 (91) 874 (87)
MAC without TBI 317 (12) 141 (9) 129 (13)
RIC 359 (14) 0 0
Graft type
Bone marrow 659 (25) 687 (42) 331 (33)
Peripheral blood 1611 (62) 239 (15) 431 (43)
Single cord 87 (3) 591 (37) 168 (17)
Double cords 236 (9) 102 (6) 73 (7)
Donor type
HLA-identical sibling 903 (35) 367 (23) 197 (20)
Well-matched unrelated or 8/8 934 (36) 328 (20) 334 (33)
Partially/mismatched unrelated or #7/8 433 (17) 231 (14) 231 (23)
Cord blood 323 (12) 693 (43) 241 (24)
Donor–recipient sex match
Male–male 951 (37) 548 (34) 382 (38)
Male–female 562 (22) 330 (20) 191 (19)
Female–male 559 (22) 424 (26) 248 (25)
Female–female 473 (18) 246 (15) 147 (15)
Missing 48 (2) 71 (4) 35 (3)
Data are n (%) unless otherwise indicated.
ATG, antithymocyte globulin; CNS, central nervous system; NA, not applicable (before the year 2007); PIF, primary induction failure; TCD, T-cell depletion; TKI, tyrosine kinase inhibitor; WBC, white blood cell.
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aGVHD, respectively. The cumulative incidences of grades I and
II and grades III and IV aGVHD by day 100 were 42% and 19%.
The cumulative incidence of cGVHD at 1 year was 29%, and 30%
never developed GVHD. The 1- and 5-year cumulative incidence rates
of relapse were 20% and 30%, and the corresponding NRM rates
were 14% and 17%. The 1- and 5-year OS rates were 73% and 59%.
In MVA, using no GVHD as the reference category, grades I and II
aGVHD and grades III and IV aGVHD were protective against
relapse (HR, 0.70 [95% CI, 0.56-0.88]; and HR, 0.70 [95% CI,
0.50-0.99], respectively). Conversely, grades III and IV aGVHD and
cGVHD with any grade of aGVHD were each associated with
increased risk of NRM (HR, 2.54-6.75). Compared with patients
without GVHD, these differential effects translated into the follow-
ing: (1) significantly improved DFS (HR, 0.74; 95% CI, 0.61-0.89)
and OS (HR, 0.77; 95% CI, 0.62-0.95) with isolated grades I and II
aGVHD; (2) significantly worse DFS and OS with grades III and IV
aGVHDwith or without cGVHD (HR, 1.59 [95%CI, 1.18-2.13] andHR,
1.76 [95% CI, 1.30-2.37], with cGVHD; HR, 1.53 [95% CI, 1.23-1.90]
and HR, 1.83 [95% CI, 1.46-2.31], without cGVHD); and (3) similar
DFS and OS with cGVHD, with or without grades I and II aGVHD.
MVA of other factors affecting OS. In the pediatric cohort,
overall mortality increased with older patient age (10-18 years) and
in CMV-seropositive patients with a CMV-seronegative donor. OS
improved in the more recent transplant era. Subgroup analyses
yielded similar results within the CR1 and CR2 cohorts (data not
shown).
Adult and pediatric patients with advanced disease
Influence of aGVHD and cGVHD on transplant outcomes.
The median follow-up of survivors was 86 months (range, 3-176
months). At the time of analysis, 29% (293 of 1003) of patients
with advanced disease were alive, and 181 (18%), 239 (24%),
163 (16%), and 78 (8%) patients developed grades I, II, III and IV
aGVHD, respectively. The cumulative incidences of grades I and
II and grades III and IV aGVHD by day 100 were 42% and 23%.
The cumulative incidence of cGVHD at 1 year was 29%, and 27%
never developed GVHD. The 1- and 5-year cumulative incidence rates
of relapsewere 36%and 44%, and the corresponding NRM rates were
26% and 32%. The 1- and 5-year survival rates were 47% and 27%.
InMVA, using noGVHD as the reference category, only grades III and
IV aGVHD and de novo cGVHD were protective against leukemia
relapse (HR, 0.66 [95% CI, 0.47-0.92]; and HR, 0.53 [95% CI,
0.32-0.86], respectively). Conversely, patients with grades III and IV
aGVHD with or without cGVHD were at increased risk of NRM
(HR, 2.38 [95% CI, 1.54-3.68]; and HR, 2.69 [95% CI, 1.95-3.70])
(Figure 2). Compared with patients without GVHD, these differential
effects translated into the following: (1) significantly improved DFS
and a trend to better OS among patients with isolated grades I and II
aGVHD (HR, 0.80 [95%CI, 0.65-0.98]; and HR, 0.81 [95%CI, 0.66-
1.01]); (2) significantly worse DFS among patients with isolated
grades III and IV aGVHD (HR, 1.36; 95% CI, 1.09-1.70); (3)
significantly improved OS among patients with cGVHD with or
without grades I and II aGVHD (HR, 0.73 [95% CI, 0.56-0.95]; and
Table 1. (continued)
Variable Adults, CR1/CR2, MAC/RIC Pediatrics, CR1/CR2, MAC All ages PIF/relapse/CR ‡3, MAC
Donor–recipient CMV serology
1/1 763 (29) 249 (15) 227 (23)
1/2 255 (10) 115 (7) 80 (8)
2/1 781 (30) 538 (33) 346 (34)
2/2 676 (26) 665 (41) 302 (30)
Missing 118 (5) 52 (3) 48 (5)
URD age, median (range), y 33 (19-57) 33 (18-57) 34 (19-57)
GVHD prophylaxis
CNI 1 MTX 1684 (65) 882 (54) 621 (62)
CNI 1 MMF 549 (21) 327 (20) 207 (21)
Other 357 (14) 410 (25) 172 (17)
Missing 3 (,1) 0 3 (,1)
In vivo TCD (ATG or alemtuzumab)
No 2048 (79) 991 (61) 712 (71)
Yes 544 (21) 628 (39) 290 (29)
Missing 1 (,1) 0 1 (,1)
Year of HCT
2000-2003 597 (23) 494 (31) 376 (37)
2004-2007 897 (35) 580 (36) 372 (37)
2008-2011 619 (24) 337 (21) 175 (17)
2012-2014 480 (19) 208 (13) 80 (8)
Median follow-up of survivors (range), mo 70 (2-184) 72 (2-191) 86 (3-176)
Data are n (%) unless otherwise indicated.
ATG, antithymocyte globulin; CNS, central nervous system; NA, not applicable (before the year 2007); PIF, primary induction failure; TCD, T-cell depletion; TKI, tyrosine kinase inhibitor; WBC, white blood cell.
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HR, 0.69 [95% CI, 0.48-0.97]); and (4) significantly worse OS
among patients with grades III and IV aGVHD without cGVHD
(HR, 1.73; 95% CI, 1.38-2.18).
MVA of other factors affecting OS. Overall mortality
increased with older age and KPS scores ,90%. Patients with
Philadelphia-positive ALL had better OS than patients with
SR-cytogenetics, whereas patients with poor risk cytogenetics
had worse OS compared with patients with SR-cytogenetics. OS
was worse using matched/mismatched URD or UCB compared
with MSD. CMV-seronegative patients with CMV-seronegative or
positive donors had better OS than CMV-seropositive patients
with CMV-seropositive donors. Other favorable factors included
GVHD prophylaxis using a CNI plus methotrexate and transplants
in the more recent era.
Discussion
The differential GVL effect in ALL based on aGVHD severity and
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F
Figure 1. NRM and relapse, DFS, and OS in 3 cohorts. Relapse and NRM for adults (CR1/CR2) (A), pediatric patients (CR1/CR2, MAC) (C), and all patients with active
disease (MAC) (E). DFS and OS for adults (CR1/CR2) (B), pediatric patients (CR1/CR2, MAC) (D), and all patients with active disease (MAC) (F).
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patients facilitated by the CIBMTR. These data indicate that severe
aGVHD is no more protective against relapse than mild aGVHD.
Most importantly, the net survival advantage of GVL in ALL is
confined to adult and pediatric patients in CR1/CR2 experiencing
maximum grades I and II aGVHD without cGVHD. Because grades
I and II aGVHD do not increase NRM while they are associated with
significant protection against relapse, they consequently yield the
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Figure 2. Forest plot of main effect in time-dependent MVA models. The larger size of box indicates larger cohort.
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without GVHD); cGVHD is associated with increased NRM, which
abrogates any relapse-protective effect of GVHD. In addition, the
poor survival in patients with advanced ALL, which is mainly attributed
to relapse/progression, is nevertheless significantly improved in the
presence of cGVHD (27%-32% lower risk of overall mortality) and
has a trend toward improved survival with grades I and II aGVHD
Table 2. Multivariate analyses of factors affecting OS
Variable
Adults, CR1/CR2, MAC/RIC (n 5 2593) Pediatrics, CR1/CR2, MAC (n 5 1619) Advanced disease, MAC (n 5 1003)
n HR (95% CI) P n HR (95% CI) P n HR (95% CI) P
Age, y
1-9 941 1 187 1
10-18 678 1.43 (1.22-1.68) ,.0001 225 0.97 (0.75-1.25) .80
19-29 928 1 281 1.39 (1.07-1.79) .012
30-39 568 1.03 (0.89-1.20) .68 139 1.26 (0.93-1.70) .13
40-49 558 1.28 (1.10-1.49) .0015 107 2.10 (1.53-2.89) ,.0001
50-59 402 1.66 (1.40-1.97) ,.0001 67 1.58 (1.10-2.29) .015
$60 137 1.61 (1.20-2.15) .0013 7 3.68 (1.40-9.68) .0084
KPS score
,90% 733 1 293 1
90%-100% 1774 0.78 (0.69-0.88) ,.0001 648 0.81 (0.68-0.95) .011
Missing 86 0.90 (0.66-1.21) .47 62 0.78 (0.56-1.09) .15
Cytogenetics
Normal/standard 1196 1 513 1
Poor, Philadelphia positive 957 0.83 (0.73-0.94) .0029 150 0.77 (0.60-0.97) .028
Poor, Philadelphia negative 230 1.09 (0.89-1.32) .41 95 1.41 (1.09-1.84) .010
Missing 210 1.18 (0.97-1.44) .092 245 0.91 (0.75-1.09) .30
Conditioning
MAC with TBI 1917 1
MAC without TBI 317 1.29 (1.09-1.53) .0026
RIC 359 1.06 (0.88-1.27) .57
Donor source
Matched sibling 903 1 197 1
Matched URD 934 1.08 (0.95-1.24) .25 334 1.40 (1.11-1.76) .0044
Mismatched URD 433 1.39 (1.18-1.64) ,.0001 231 1.84 (1.44-2.35) ,.0001
UCB 323 1.23 (0.98-1.53) .077 241 1.37 (1.00-1.87) .049
D/R CMV serology
1/1 763 1 249 1 227 1
1/2 255 0.91 (0.75-1.11) .36 115 1.08 (0.75-1.54) .69 80 0.66 (0.48-0.89) .0074
2/1 781 0.86 (0.74-1.00) .050 538 1.35 (1.06-1.72) .017 346 0.82 (0.66-1.02) .069
2/2 767 0.83 (0.71-0.97) .018 665 0.94 (0.73-1.20) .60 302 0.59 (0.47-0.74) ,.0001
Missing 118 1.19 (0.92-1.53) .18 52 0.94 (0.58-1.51) .79 48 1.06 (0.73-1.53) .77
GVHD prophylaxis
CNI 1 MTX 1684 1 621 1
CNI 1 MMF 549 1.23 (1.06-1.45) .0087 207 1.30 (1.03-1.64) .026
Other 357 1.10 (0.93-1.30) .24 172 0.97 (0.77-1.23) .82
Year of transplantation
2000-2003 597 1 494 1 376 1
2004-2007 897 0.90 (0.79-1.04) .16 580 0.74 (0.61-0.89) .0013 372 0.78 (0.65-0.93) .0059
2008-2011 619 0.80 (0.68-0.95) .0086 337 0.66 (0.53-0.83) .00040 175 0.62 (0.49-0.80) .00020
2012-2014 480 0.64 (0.52-0.78) ,.0001 208 0.66 (0.50-0.88) .0050 80 0.54 (0.38-0.78)
GVHD is shown separately in Figure 2.
D/R, donor/recipient; MMF, mycophenolate mofetil; MTX, methotrexate; PIF, primary induction failure.
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(P 5 .056). Most importantly, in all disease cohorts, grades III
and IV aGVHD with their two- to sixfold increase in NRM substan-
tially decrease survival despite their favorable effect on disease
relapse.23
In an attempt to determine any favorable net impact of mild
aGVHD (grades I and II; 42% of recipients) on survival, we
separately compared grades I and II aGVHD and grades III and IV
aGVHD vs no GVHD. Indeed, more conventional comparisons of
grades 0 and I vs grades II to IV aGVHD12,13,15 failed to uncover our
findings (data not shown). Thus, we suggest that clinical discrim-
ination and separate analyses of survivable grades I and II acute
GVHD and severe grades III and IV aGVHD should be applied in
future similar studies.
By examining 3 different cohorts of patients, our analysis revealed
that GVHD-associated GVL and GVHD-associated NRM translate
differently according to leukemia remission status but are remarkably
similar in adult and pediatric patients with ALL in CR1/CR2. It is
important to notice that subgroup analyses within CR1 and CR2
showed similar HR in the same direction, justifying the CR1/CR2
joined analysis as presented here. Although it was not the focus of
our analyses, comparing survival among the 3 cohorts supports
the prior observation that CR1/CR2 at the time of transplantation
is a strong determinant of favorable posttransplant survival. One of
the study limitations is a lack of data on pretransplant MRD in 84%
of the patients. MRD is a major factor for posttransplant survival,24
and whether the GVL effect differs in MRD-positive vs MRD-
negative settings deserves further investigation.
We compared our findings in ALL vs those of a similar
retrospective CIBMTR study conducted in AML.12 In contrast
to our findings in ALL, AML patients with aGVHD after MAC
alloHCT had a worse OS compared with patients without GVHD,
as aGVHD in AML lacked any protective effect against relapse
while it was associated with increased NRM. However, AML
patients with cGVHD only after RIC alloHCT had a better OS
compared with patients without GVHD as the cGVHD-associated
protective effect against relapse was only partially offset by
increased NRM.
Transplant pioneers described the GVL effect in ALL 40 years
ago.15 Nevertheless, previous studies did not show survival
benefit of GVHD-associated GVL due to increased NRM. In
contrast, the present study provides detailed evidence that
different grades of GVHD are associated with different levels of
protection against relapse. However, until we are better able to
ameliorate the NRM in severe GVHD, the clinical benefit and
best survival are confined to grades I and II aGVHD. Conse-
quently, our findings may potentially be used to time the
immunosuppression taper in those patients with high-risk ALL
and no GVHD. We also highlight the improvement in survival over
time: among many factors, we noted better KPS scores in
recipients over time and more common use of TKI, RIC, and
UCB grafts in the past decade.
Although our ability to tailor the most appropriate GVHD manage-
ment for each transplanted individual remains a challenge, our
findings support this nonstandard GVHD grouping for future
studies. Better methods to truncate the GVHD progression and
strategies to improve quality of life in cGVHD must be developed
to better harness the powerful GVL effect in ALL.
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